dc.contributor.author | Antunes, Liliana | |
dc.contributor.author | Mazagatos, Clara | |
dc.contributor.author | Martínez-Baz, Iván | |
dc.contributor.author | Gomez, Verónica | |
dc.contributor.author | Borg, Maria-Louise | |
dc.contributor.author | Petrović, Goranka | |
dc.contributor.author | Duffy, Róisín | |
dc.contributor.author | Dufrasne, François E | |
dc.contributor.author | Dürrwald, Ralf | |
dc.contributor.author | Lazar, Mihaela | |
dc.contributor.author | Jancoriene, Ligita | |
dc.contributor.author | Oroszi, Beatrix | |
dc.contributor.author | Husa, Petr | |
dc.contributor.author | Howard, Jennifer | |
dc.contributor.author | Melo, Aryse | |
dc.contributor.author | Pozo Sanchez, Francisco | |
dc.contributor.author | Pérez-Gimeno, Gloria | |
dc.contributor.author | Castilla, Jesús | |
dc.contributor.author | Machado, Ausenda | |
dc.contributor.author | Džiugytė, Aušra | |
dc.contributor.author | Karabuva, Svjetlana | |
dc.contributor.author | Fitzgerald, Margaret | |
dc.contributor.author | Fierens, Sébastien | |
dc.contributor.author | Tolksdorf, Kristin | |
dc.contributor.author | Popovici, Silvia-Odette | |
dc.contributor.author | Mickienė, Auksė | |
dc.contributor.author | Túri, Gergő | |
dc.contributor.author | Součková, Lenka | |
dc.contributor.author | Nicolay, Nathalie | |
dc.contributor.author | Rose, Angela Mc | |
dc.contributor.author | European Hospital Vaccine Effectiveness Group | |
dc.date.accessioned | 2024-03-18T16:53:51Z | |
dc.date.available | 2024-03-18T16:53:51Z | |
dc.date.issued | 2024-01 | |
dc.identifier.citation | Euro Surveill. 2024 Jan;29(3):2300708. | es_ES |
dc.identifier.uri | http://hdl.handle.net/20.500.12105/18998 | |
dc.description.abstract | We conducted a multicentre hospital-based test-negative case-control study to measure the effectiveness of adapted bivalent COVID-19 mRNA vaccines against PCR-confirmed SARS-CoV-2 infection during the Omicron XBB lineage-predominant period in patients aged ≥ 60 years with severe acute respiratory infection from five countries in Europe. Bivalent vaccines provided short-term additional protection compared with those vaccinated > 6 months before the campaign: from 80% (95% CI: 50 to 94) for 14-89 days post-vaccination, 15% (95% CI: -12 to 35) at 90-179 days, and lower to no effect thereafter. | es_ES |
dc.description.sponsorship | The Vaccine Effectiveness, Burden and Impact Studies studies (VEBIS) is a project of the European Centre for Disease Prevention and Control (ECDC) run under the framework contract No. ECDC/2021/016. | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | European Centre for Disease Prevention and Control (ECDC) | es_ES |
dc.type.hasVersion | VoR | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
dc.subject | COVID-19 | es_ES |
dc.subject | COVID-19 bivalent vaccines | es_ES |
dc.subject | Europe | es_ES |
dc.subject | Hospitalisation | es_ES |
dc.subject | SARI | es_ES |
dc.subject | SARS-CoV-2 | es_ES |
dc.subject | Vaccine effectiveness | es_ES |
dc.subject | XBB | es_ES |
dc.subject.mesh | COVID-19 Vaccines | es_ES |
dc.subject.mesh | COVID-19 | es_ES |
dc.subject.mesh | Humans | es_ES |
dc.subject.mesh | Case-Control Studies | es_ES |
dc.subject.mesh | SARS-CoV-2 | es_ES |
dc.subject.mesh | Hospitalization | es_ES |
dc.subject.mesh | Europe | es_ES |
dc.subject.mesh | RNA, Messenger | es_ES |
dc.title | Effectiveness of the adapted bivalent mRNA COVID-19 vaccines against hospitalisation in individuals aged ≥ 60 years during the Omicron XBB lineage-predominant period: VEBIS SARI VE network, Europe, February to August, 2023 | es_ES |
dc.type | research article | es_ES |
dc.rights.license | Atribución 4.0 Internacional | * |
dc.identifier.pubmedID | 38240061 | es_ES |
dc.format.volume | 29 | es_ES |
dc.format.number | 3 | es_ES |
dc.format.page | 2300708 | es_ES |
dc.identifier.doi | 10.2807/1560-7917.ES.2024.29.3.2300708 | es_ES |
dc.contributor.funder | Unión Europea. European Centre for Disease Prevention and Control (ECDC) | es_ES |
dc.description.peerreviewed | Sí | es_ES |
dc.identifier.e-issn | 1560-7917 | es_ES |
dc.relation.publisherversion | https://doi.org/10.2807/1560-7917.ES.2024.29.3.2300708 | es_ES |
dc.identifier.journal | Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin | es_ES |
dc.repisalud.centro | ISCIII::Centro Nacional de Epidemiología | es_ES |
dc.repisalud.centro | ISCIII::Centro Nacional de Microbiología | es_ES |
dc.repisalud.institucion | ISCIII | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/EC/ECDC/2021/016 | es_ES |
dc.rights.accessRights | open access | es_ES |